Assay and drug development technologies最新文献_第3页

In Vitro Antiviral Assays: A Review of Laboratory Methods. 体外抗病毒检测：实验室方法综述。

IF 1.6 4区医学

Assay and drug development technologies Pub Date : 2025-01-13 DOI: 10.1089/adt.2024.075

Gabriel Atampugbire, Eureka Emefa Ahadjie Adomako, Osbourne Quaye

引用次数: 0

Optimization of Docetaxel-Zedoary Turmeric Oil Magnetic Solid Lipid Nanoparticle Preparation by Central Composite Design-Response Surface Methodology. 多西他赛-莪术油磁性固体脂质纳米粒制备的中心复合设计-响应面法优化。

IF 1.6 4区医学

Assay and drug development technologies Pub Date : 2025-01-08 DOI: 10.1089/adt.2024.120

Yujiao Hou, Yuesheng Zhao, Jun Liu, Yanan Bao, Njolibimi Mosesmanaanye, Chunjie Zhao, Wenjing Li, Bo Hong

{"title":"Optimization of Docetaxel-Zedoary Turmeric Oil Magnetic Solid Lipid Nanoparticle Preparation by Central Composite Design-Response Surface Methodology.","authors":"Yujiao Hou, Yuesheng Zhao, Jun Liu, Yanan Bao, Njolibimi Mosesmanaanye, Chunjie Zhao, Wenjing Li, Bo Hong","doi":"10.1089/adt.2024.120","DOIUrl":"https://doi.org/10.1089/adt.2024.120","url":null,"abstract":"To optimize the formulation of docetaxel-zedoary oil magnetic solid lipid nanoparticles (DTX-ZTO-MSLN) using central composite design-response surface methodology. First, the formulation and preparation process of DTX-ZTO-MSLN were optimized via design-response surface methodology. The appearance, particle size, thermogravimetric, pH, iron content, magnetic strength, and in vitro drug release of DTX-ZTO-MSLN were subsequently examined. Finally, the antitumor effect of DTX-ZTO-MSLN on MCF-7 breast cancer cells was measured via the 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay. The optimized formulation was as follows: the mass ratio of soybean phospholipid to poloxamer 188 was 0.34, the mass ratio of DTX-ZTO to glycerol monostearate was 3.23, and 29.42 mL of water was used. The DTX-ZTO-MSLN prepared by the optimized method was clear and transparent, with good stability, with an iron content of 7.38%, and a saturation magnetization intensity of 7.05 A·m2·kg-1. The in vitro drug release was consistent with the Weibull model (R2 = 0.9992). Compared with zedoary turmeric oil and docetaxel, DTX-ZTO-MSLN had a much greater inhibitory effect on MCF-7 cells (p < 0.05). The optimized DTX-ZTO-MSLN meets the quality requirements for nanoemulsions. This study provides a theoretical basis for developing and applying DTX-ZTO-MSLN.","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142943401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug Repurposing Patent Applications July-September 2024. 药物再利用专利申请2024年7月至9月。

IF 1.6 4区医学

Assay and drug development technologies Pub Date : 2025-01-01 Epub Date: 2024-11-29 DOI: 10.1089/adt.2024.126

Hermann A M Mucke

引用次数: 0

Editorial: A New Chapter in Assay and Drug Development Technologies. 社论：化验和药物开发技术的新篇章。

IF 1.6 4区医学

Assay and drug development technologies Pub Date : 2025-01-01 Epub Date: 2024-11-28 DOI: 10.1089/adt.2024.131

Kevin W H Lo

引用次数: 0

Acknowledgment of Reviewers 2024. 审稿人致谢

IF 1.6 4区医学

Assay and drug development technologies Pub Date : 2025-01-01 DOI: 10.1089/adt.2024.10910.revack

引用次数: 0

Nanocarrier-Mediated Dermal Drug Delivery System of Antimicrobial Agents for Targeting Skin and Soft Tissue Infections. 针对皮肤和软组织感染的纳米载体皮肤给药系统。

IF 1.6 4区医学

Assay and drug development technologies Pub Date : 2025-01-01 Epub Date: 2024-11-26 DOI: 10.1089/adt.2024.060

Priya, Praveen Kumar Gaur, Shobhit Kumar

{"title":"Nanocarrier-Mediated Dermal Drug Delivery System of Antimicrobial Agents for Targeting Skin and Soft Tissue Infections.","authors":"Priya, Praveen Kumar Gaur, Shobhit Kumar","doi":"10.1089/adt.2024.060","DOIUrl":"10.1089/adt.2024.060","url":null,"abstract":"\u0000 Antimicrobial resistance in disease-causing microbes is seen as a severe problem that affects the entire world, makes therapy less effective, and raises mortality rates. Dermal antimicrobial therapy becomes a desirable choice in the management of infectious disorders since the rising resistance to systemic antimicrobial treatment frequently necessitates the use of more toxic drugs. Nanoparticulate systems such as nanobactericides, which have built-in antibacterial activity, and nanocarriers, which function as drug delivery systems for conventional antimicrobials, are just two examples of the treatment methods made feasible by nanotechnology. Silver nanoparticles, zinc oxide nanoparticles, and titanium dioxide nanoparticles are examples of inorganic nanoparticles that are efficient on sensitive and multidrug-resistant bacterial strains both as nanobactericides and nanocarriers. To stop the growth of microorganisms that are resistant to standard antimicrobials, various antimicrobials for dermal application are widely used. This review covers the most prevalent microbes responsible for skin and soft tissue infections, techniques to deliver dermal antimicrobials, topical antimicrobial safety concerns, current issues, challenges, and potential future developments. A thorough and methodical search of databases, such as Google Scholar, PubMed, Science Direct, and others, using specified keyword combinations, such as \"antimicrobials,\" \"dermal,\" \"nanocarriers,\" and numerous others, was used to gather relevant literature for this work.\u0000 ","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"2-28"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preparation, Characterization, and In Vitro Evaluation of Chlorogenic Acid Loaded Hydrogel Beads for the Management of Ulcerative Colitis. 绿原酸负载水凝胶珠治疗溃疡性结肠炎的制备、表征和体外评价。

IF 1.6 4区医学

Assay and drug development technologies Pub Date : 2025-01-01 Epub Date: 2024-12-04 DOI: 10.1089/adt.2024.072

Ranjit K Harwansh, Hemant Bhati, Rohitas Deshmukh, Mohammad Akhlaquer Rahman

{"title":"Preparation, Characterization, and In Vitro Evaluation of Chlorogenic Acid Loaded Hydrogel Beads for the Management of Ulcerative Colitis.","authors":"Ranjit K Harwansh, Hemant Bhati, Rohitas Deshmukh, Mohammad Akhlaquer Rahman","doi":"10.1089/adt.2024.072","DOIUrl":"10.1089/adt.2024.072","url":null,"abstract":"\u0000 Ulcerative colitis (UC) is a chronic inflammatory colon disorder. Several modern medicines have been used for UC treatment but are associated with side effects. Hence, herbal medicine-inspired lead molecules are promising for managing UC. Chlorogenic acid (CGA), an herbal bioactive, has been reported for anti-inflammatory, anticancer, antioxidant, and immunomodulatory activity. The current study aimed to develop enteric-coated mucoadhesive beads of CGA for colon targeting. CGA-loaded beads were prepared using chitosan and carrageenan as polymers through an ionic gelation technique. Furthermore, beads were coated with Eudragit S-100. The formulations were characterized by particle size analyzer, ultraviolet (UV)-spectroscopy, Fourier transform infrared spectroscopy (FTIR), scanning electron microscope (SEM), and in vitro drug release study. The optimized formulation (CGA-F2) showed particle size (440.6 ± 6.1 μm), zeta potential (-31.12 ± 2.16 mV), entrapment efficiency (83.56 ± 5.46), %yield (86.87 ± 4.19), and drug loading (1.14 ± 0.09). SEM indicated that the morphologies of CGA-F2 were spherical and ellipsoidal. The FTIR study confirmed the compatibility of the drug with polymers used in the formulations. CGA-F2 exhibited mucoadhesive efficiency (94.33 ± 2.1%) and swelling index (0.98 ± 0.03) at simulated colonic fluid (SCF) pH 7.4 (***p < 0.001) significantly. In an in vitro drug release study, CGA-F2 (95.07 ± 3.85%) showed a sustained drug release profile in SCF (pH 7.4) at 37 ± 0.5°C for 24 h. Optimized formulation exhibited drug release in a sustained manner for 24 h, which may be due to the effect of mucoadhesive and enteric coating polymer. Hence, CGA-loaded beads would be promising for treating the UC.\u0000 ","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"29-43"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ligandrol Ameliorates High-Fat Diet- and Streptozotocin-Induced Type 2 Diabetes Mellitus and Prevents Pancreatic Islets Degeneration. 利甘定能改善高脂饮食和链脲佐菌素诱发的 2 型糖尿病并防止胰岛退化

IF 1.6 4区医学

Assay and drug development technologies Pub Date : 2024-11-01 Epub Date: 2024-11-06 DOI: 10.1089/adt.2024.029

Deepa Sugumar, Ritaban Ghosh, Emdormi Rymbai, Jaikanth Chandrasekaran, Praveen Thaggikuppe Krishnamurthy, Ranjith S P, Shreya Sahu, Divakar Selvaraj

{"title":"Ligandrol Ameliorates High-Fat Diet- and Streptozotocin-Induced Type 2 Diabetes Mellitus and Prevents Pancreatic Islets Degeneration.","authors":"Deepa Sugumar, Ritaban Ghosh, Emdormi Rymbai, Jaikanth Chandrasekaran, Praveen Thaggikuppe Krishnamurthy, Ranjith S P, Shreya Sahu, Divakar Selvaraj","doi":"10.1089/adt.2024.029","DOIUrl":"10.1089/adt.2024.029","url":null,"abstract":"Androgen therapy has been shown to alleviate type 2 diabetes mellitus (T2DM) but is also associated with severe side effects such as prostate cancer. The present study aims to identify the best hit selective androgen receptor (AR) modulator by in silico studies and then investigates its antidiabetic effects in high-fat diet- and streptozotocin (STZ)-induced T2DM male rat model. Molecular docking and molecular dynamics (MD) studies were carried out using Maestro 13.1 and Desmond (2023-2024). Cytotoxicity and insulin secretion were measured in MIN6 cell lines. T2DM was induced using high-fat diet (HFD) for 4 weeks, followed by single STZ (40 mg/kg, intraperitoneally). OneTouch Ultra glucometer was used to measure fasting blood glucose. Gene expression was determined using reverse transcription polymerase chain reaction. Histopathology was carried out using hematoxylin and eosin stain. Through molecular docking, we identify ligandrol as a potential hit. Ligandrol showed a good binding affinity (-10.74 kcal/mol). MD showed that ligandrol is stable during the 100 ns simulation. Ligandrol increases insulin secretion in a dose-dependent manner in vitro in 2 h. Ligandrol (0.3 and 1 mg/kg, orally) significantly decreased the body weight and fasting blood glucose levels compared with the HFD and STZ group. Gene expression showed that ligandrol significantly increased the AR-targeted gene, neurogenic differentiation 1, compared with the HFD and STZ group. Histopathological staining studies showed that ligandrol prevents pancreatic islet degeneration compared with the HFD and STZ group. Our findings suggest that ligandrol's protective effect on pancreatic islets leading to its antidiabetic effect occurs through the activation of AR.","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"397-408"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142581919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reverse Phase-High-Performance Liquid Chromatography (RP-HPLC) Method Development and Validation Using Analytical Quality-by-Design Approach for Determination of Isoliquiritigenin in Bulk and Biological Sample. 采用 "分析质量源于设计 "方法开发和验证反相高效液相色谱 (RP-HPLC) 方法，用于测定大宗样品和生物样品中的异桔梗苷元。

IF 1.6 4区医学

Assay and drug development technologies Pub Date : 2024-11-01 Epub Date: 2024-11-25 DOI: 10.1089/adt.2024.050

Mohamed Nihal P, Debasish Mohapatra, Alam Mohd Adil Alam Manir, Vancha Harish, Sachin Kumar Singh, Sakshi Upendra Lad, Srinivas Sutrapu, Sumant Saini, Sharfuddin Mohd

{"title":"Reverse Phase-High-Performance Liquid Chromatography (RP-HPLC) Method Development and Validation Using Analytical Quality-by-Design Approach for Determination of Isoliquiritigenin in Bulk and Biological Sample.","authors":"Mohamed Nihal P, Debasish Mohapatra, Alam Mohd Adil Alam Manir, Vancha Harish, Sachin Kumar Singh, Sakshi Upendra Lad, Srinivas Sutrapu, Sumant Saini, Sharfuddin Mohd","doi":"10.1089/adt.2024.050","DOIUrl":"10.1089/adt.2024.050","url":null,"abstract":"The primary objective of the present investigation is to develop and validate a simple, robust, and cost-effective isocratic reverse phase-high-performance liquid chromatography (RP-HPLC) method for determining isoliquiritigenin (ISL) in both bulk and biological samples using an analytical quality-by-design (AQbD) approach. The central composite design was employed for method optimization using Design Expert® software, by taking mobile phase ratio and flow rate as independent variables and peak area, retention time, tailing factor, and theoretical plates as dependent variables. The design suggested the use of a mobile phase consisting of acetonitrile:0.2% ortho-phosphoric acid (75:25, v/v) and a flow rate of 0.9 mL/min as optimal chromatographic conditions. The detection of ISL was performed at 364 nm. The optimized method was validated in accordance with International Conference on Harmonization (ICH) Q2(R1) guidelines. The method showed excellent linearity, limit of detection, limit of quantification, accuracy, precision, robustness, and system suitability. All validation parameters fell within the acceptable limits set by ICH. Additionally, the applicability of the method in biological samples were analyzed. In conclusion, the results suggest that the developed and validated AQbD-based RP-HPLC method was well-suited for the estimation of ISL in bulk and biological sample.","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"409-424"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Time of Transition: Looking Back with Gratitude, Forward with Optimism. 过渡时期：感恩回首，乐观前行。

IF 1.6 4区医学

Assay and drug development technologies Pub Date : 2024-11-01 Epub Date: 2024-11-12 DOI: 10.1089/adt.2024.123

Bruce J Melancon

引用次数: 0